Last edition
News about "Xolair biosimilar AVT23"
Omalizumab, the active ingredient in Xolair, is a prescription biologic used to improve the control of severe persistent allergic asthma in patients aged six years and older when blood tests confirm immunoglobulin E (IgE) involvement.
Xolair Biosimilar AVT23 | 07/10/2025 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members